Andrew Saik - 28 May 2021 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Reporting relationship: Chief Financial Officer
Issuer ticker: VYNE
Reported as of: 28 May 2021
Net transaction value: +$10,130
SEC form: 4
Accepted by SEC: 02 Jun 2021, 16:31:40 UTC
Next SEC filing: 22 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ Mutya Harsch, attorney-in-fact for Andrew Saik

Key filing fact

Andrew Saik filed Form 4 for VYNE Therapeutics Inc. (VYNE) on 02 Jun 2021.

Key facts

This page summarizes Andrew Saik's Form 4 filing for VYNE Therapeutics Inc. (VYNE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Jun 2021, 16:31.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$10,130.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VYNE transaction

Common Stock

Award

Transaction value: $10,130
Shares: +3,017
Change %: +2.7%
Price: $3.36
Shares after: 116,468
Date: 28 May 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2020 and ending on May 31, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on May 28, 2021 (the last trading day of the offering period).